# Quoin (QNRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/QNRX
## Company Profile
- Ticker: QNRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.5 USD
- Market cap: 9158386.08 USD
- Last updated: 2026-10-09
## Business Overview
### Rare Dermatology Company
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration.
### QRX003 in Netherton Syndrome
QRX003, also referred to as QYLEKI, is the company's lead topical program for Netherton syndrome. It has received orphan-drug designation in the United States, European Union, and Japan, as well as FDA Fast Track and Rare Pediatric Disease designations.
### Peeling Skin Syndrome Expansion
Quoin is expanding QRX003 into peeling skin syndrome, another rare inherited skin disorder. The FDA has cleared the investigational new drug application for this indication, allowing the company to advance a company-sponsored study in the United States and Europe.
### QRX009 Rapamycin Platform
QRX009 is a topical rapamycin formulation platform being explored in rare dermatologic conditions including pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex. Quoin plans to use investigator-sponsored work and additional regulatory filings to broaden the platform's clinical reach.
## Why The Stock Is Moving

As of Oct 9, 2026, QNRX closed down 1.10% at $4.50. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
- Submission of an additional IND for the QRX009 platform by year-end 2026.

## Recent News
- 2026-10-06 10:30 EST — [Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-acceptance-of-qrx003-paper-in-dermatology-and-th-a2a06f0c) — Source: Quoin
- 2026-09-22 12:30 EST — [Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-fda-fast-track-designation-for-qrx003-for-the-tr-271ece8c) — Source: Quoin
- 2026-09-10 12:30 EST — [Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-releases-new-netherton-now-video-aminah-s-story-featuring--408a6ab7) — Source: Quoin
- 2026-09-08 18:12 EST — [CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome](https://biopharmsignal.com/news/QNRX/correction-quoin-pharmaceuticals-announces-fda-grants-rare-pediatric-disease-des-47f5d9b6) — Source: Quoin
- 2026-09-08 12:30 EST — [Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-fda-grants-rare-pediatric-disease-designation-fo-a5e21038) — Source: Quoin